Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia.
Chow
J W
JW
Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan 48201-2021, USA.
Donahedian
S M
SM
Zervos
M J
MJ
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004452:Echocardiography; D016984:Enterococcus faecium; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D015658:HIV Infections / Q000150:complications* / Q000382:microbiology*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D014640:Vancomycin / Q000494:pharmacology; D014769:Virginiamycin / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D014640:Vancomycin